Title Colour Legend:
Green - Topic summary is available.
Orange - Topic summary is being compiled.
Red - Topic summary has no current systematic review available.

Treatments for weight gain

How is weight gain relevant for people with schizophrenia? 

Many antipsychotic medications are associated with weight gain, and various adjunctive pharmacological approaches have been investigated for this problem. Effective adjunctive pharmaceutical treatments for side effects such as weight gain increase adherence to antipsychotic medications and reduces the risk of psychotic relapse.

 

What is the evidence for adjunctive pharmaceutical therapies for weight reduction?

Moderate quality evidence suggests a benefit of adjunctive topiramate, metformin, or aripiprazole for reducing weight in people with schizophrenia. Triglycerides, glucose, insulin and cholesterol levels may also be improved with metformin.

Moderate to low quality evidence suggests a benefit of adjunctive sibutramine or reboxetine, but no benefit of adjunctive amantadine, fluoxetine, rosiglitazone famotidine, nizatidine, norepinephrine, orlistat, or metformin + sibutramine.

Moderate quality evidence suggests switching antipsychotic medications from olanzapine to aripiprazole or quetiapine may reduce weight and blood glucose levels. There may also be improved global mental state when switching from olanzapine to aripiprazole.

Also see the relevant Pharmaceutical side effects topic, the Psychosocial treatments for weight gain topic,and the Course and Outcome diet topic.

June 2016

Page last updated: 0:06  7 September 2017

To view documentation related to this topic download the files below